News

The onset of Alzheimer’s disease, as well as its symptoms, may be slowed down by a natural compound present in pomegranates, according to research conducted at the University of Huddersfield, in West Yorkshire, UK. During his two-year project, Dr. Olumayokun Olajide, a specialist in anti-inflammatory properties of natural…

A team of researchers who conducted an eight-year study of elderly people believe they have found a relationship between depression and dementia that suggests that treating the first can reduce a part of the effects of the second. The study, published in the journal Neurology, indicates that older people…

Scientists from the Boston University School of Medicine (BUSM) believe they have found modifications in a new gene, PLXNA4, which may be a risk factor in Alzheimer’s Disease (AD) development. According to a recent article on Genetic Engineering News, researchers used data from a previous study, the…

Bioengineers at the University of Washington have designed peptide structures that can neutralize the conversion of a protein from its normal state into an abnormally folded, toxic form, preventing more than 40 amyloid diseases such as Alzheimer’s, Parkinson’s or Type 2 diabetes, for example. Ultimately, this could allow doctors…

A group of scientists is researching the possibility of utilizing a set of compounds developed for cancer treatment as a novel oral therapy for treating Alzheimer’s disease. Up until now, the team had only tested and evaluated injected epothilone D, a brain-penetrant MT-stabilizer, in mice and AD patients. However, in spite of the fact…

An abnormal protein in the brain may play an important role in the onset of Alzheimer’s disease, a group of scientists at the Mayo Clinic discovered. Although they still haven’t figured out whether this protein, called TAR DNA binding protein of 43kDa (TDP-43), is a cause of Alzheimer’s disease…

A drug prescribed for the treatment of arthritis is able to slow the progression of Alzheimer’s, according a study performed by researchers at the University of Southampton in the United Kingdom. Etanercept was administrated to patients with mild to moderate disease, and within a six-month period, the scientists verified that the…

As a result of new research conducted at the Mayo Clinic, patients with Alzheimer’s may all commonly share a newly discovered protein called TDP-43 as a potential cause for their disease, in addition to the well-known amyloid and tau proteins. Dr. Keith Josephs at the Mayo Clinic was the lead expert…